Jacobs Levy Equity Management Inc. Has $6.02 Million Holdings in DexCom, Inc. (NASDAQ:DXCM)

Jacobs Levy Equity Management Inc. boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 123.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 77,401 shares of the medical device company's stock after purchasing an additional 42,792 shares during the period. Jacobs Levy Equity Management Inc.'s holdings in DexCom were worth $6,019,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of DXCM. Private Trust Co. NA lifted its holdings in shares of DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after acquiring an additional 245 shares in the last quarter. Optiver Holding B.V. acquired a new position in shares of DexCom during the 4th quarter valued at $33,000. TD Private Client Wealth LLC lifted its holdings in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock valued at $34,000 after acquiring an additional 167 shares in the last quarter. Larson Financial Group LLC lifted its holdings in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock valued at $37,000 after acquiring an additional 137 shares in the last quarter. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom during the 4th quarter valued at $38,000. Hedge funds and other institutional investors own 97.75% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on DXCM. Morgan Stanley lifted their price target on shares of DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a research note on Friday, February 14th. Barclays boosted their target price on shares of DexCom from $90.00 to $93.00 and gave the stock an "equal weight" rating in a research report on Monday, May 5th. Robert W. Baird dropped their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating for the company in a research report on Friday, May 2nd. Mizuho started coverage on shares of DexCom in a research report on Thursday, April 10th. They issued an "outperform" rating and a $85.00 target price for the company. Finally, Canaccord Genuity Group boosted their target price on shares of DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research report on Friday, May 2nd. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $98.11.

Insider Buying and Selling at DexCom

In related news, CEO Kevin R. Sayer sold 32,498 shares of the firm's stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the transaction, the chief executive officer now directly owns 372,029 shares in the company, valued at approximately $26,183,401.02. This trade represents a 8.03% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jereme M. Sylvain sold 7,000 shares of the firm's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the transaction, the executive vice president now owns 135,482 shares in the company, valued at $10,002,636.06. The trade was a 4.91% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 66,926 shares of company stock worth $4,734,384. 0.32% of the stock is currently owned by company insiders.

DexCom Price Performance

DXCM stock traded down $0.19 on Friday, hitting $85.48. 3,397,377 shares of the company's stock traded hands, compared to its average volume of 4,356,519. DexCom, Inc. has a 1-year low of $57.52 and a 1-year high of $132.26. The stock has a market cap of $33.52 billion, a price-to-earnings ratio of 59.78, a P/E/G ratio of 2.30 and a beta of 1.43. The stock has a fifty day moving average of $72.01 and a 200-day moving average of $77.60. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). The firm had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1.02 billion. DexCom had a net margin of 14.29% and a return on equity of 30.14%. The firm's revenue was up 12.5% compared to the same quarter last year. During the same quarter last year, the company posted $0.32 EPS. On average, analysts forecast that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.